Item 8.01. Other Events.

On October 27, 2020, REGENXBIO Inc. (the "Company") announced that it will receive a milestone payment of $80.0 million from Novartis AG ("Novartis") pursuant to the License Agreement dated March 21, 2014 between the Company and AveXis, Inc., as amended on January 8, 2018. The milestone payment relates to the successful achievement of $1 billion in cumulative net sales of Novartis's Zolgensma and is expected to be received in October 2020.

A copy of the Company's press release announcing the expected milestone payment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d)  Exhibits



Exhibit
  No.       Description

99.1          REGENXBIO Inc. Press Release dated October 27, 2020.

104         The cover page from this Current Report on Form 8-K, formatted in
            Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses